Author:
Kroschinsky Frank,Schleyer Eberhard,Renner Ulf,Schimming Claudia,Schimmelpfennig Christoph,Bornhäuser Martin,Illmer Thomas,Trümper Lorenz,Ehninger Gerhard,Schaich Markus
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference47 articles.
1. Åleskog A, Jonsson E, Larsson R, Nygren P, Kristensen J, Sundström C, Höglund M (2002) In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma. Br J Haematol 117:563
2. Aviles A, Nambo MJ, Talavera A, Garcia EL, Huerta-Guzman J, Diaz Maqueo JC (1997) Epirubicin (CEOP-Bleo) versus idarubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies. Anticancer Drugs 8:937
3. Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267
4. Bertelli G, Amoroso D, Pronzato P, Rosso R (1988) Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors. Anticancer Res 8:645
5. Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, Meneghini V, Orlandi E, Orsucci L, Pizzuti M, Scalabrini DR, Salvi F, Todeschini G, Vitolo U, Resegotti L (1997) Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A=doxorubicin) vs VICOP-B (I=idarubicin). Haematologica 82:309